ArticleDigestive diseases and sciences2026
Deciphering Cancer Evolution Through Genomic Profiling of Patient-Derived Xenograft Together with Matched Primary Gallbladder Cancer.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder cancer has a poor prognosis due to its aggressive nature and late detection. Adenosquamous subtypes are rare and poorly characterized at the molecular level. Patient-derived xenograft (PDX) models preserve tumor heterogeneity and support evolutionary studies. Longitudinal specimens-primary, metastatic, and PDX-from the same patient, combined with immunohistochemistry (IHC), allow investigation of tumor progression and cellular origin. METHODOLOGY: A 65-year-old woman with gallbladder cancer underwent cholecystectomy, followed by omental metastasectomy upon relapse. A single-cell suspension from the metastatic lesion was injected into NOD-SCID mice to generate a PDX model. IHC assessed marker expression in primary, metastatic, and PDX tumors. A targeted next-generation sequencing somatic panel analyzed clonal evolution.
resultsP63 confirmed the adenosquamous subtype. The PDX model retained histopathological and marker features of the primary and metastatic tumors. Diagnostic (CK7, CK17, Muc1, Muc5AC) and prognostic markers (EpCAM, CRP, S100P, AQP1, Podoplanin) were preserved across all tumors. Genomic analysis identified KRAS (G12V) mutation as the main oncogenic driver and LRP1B (Q48R) mutation as a putative tumor suppressor retained in all tumors. The secondary tumor acquired PIK3CA (E65D) and LRP1B (G37437) mutations. The PDX gained mutations in chromatin remodeling genes ARID2, ARID1A, and BAP1. Clonal trajectory analysis identified four subclones, indicating branched and linear evolution patterns.
conclusionWe successfully established a PDX model of gallbladder adenosquamous carcinoma, with KRAS (G12V) identified as a potential initiating mutation, and the probable tumor-initiating cell is derived from an EpCAM-positive putative cancer stem cell. Sequential analysis revealed the emergence of resistant clones and adaptive selection of chromatin remodelers in the PDX model.
Indexed as
Identifiers
41207908What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.